Home | News | Find a Doctor | Ask a Question | Free

Intercytex shares waaaaaay down


#1

Found this posted on another site.
http://uk.finance.yahoo.com/q?s=icx&m=L&d=


http://www.investegate.co.uk/Article.aspx?id=200901260700081866M<br%20/>


#2

I am not surprised at all. In fact, I predicted this.
Cyzact (ICX-PRO), has failed phase III trials.
This is the product where ICX was spending most of its money.
Not surprisingly, stocks have drop 74% today. Yes, 74%.
Thus, ICX is over.

http://finance.yahoo.com/q/bc?s=ICX.L&t=3m&l=on&z=m&q=l&c=


http://www.reuters.com/article/rbssHealthcareNews/idUSLK82692220090220

UPDATE 1-Intercytex drug misses goal, shares down
Fri Feb 20, 2009 11:06am EST Email | Print | Share| Reprints | Single Page[-] Text [+]
Market News
Stocks cut losses after White House bank comment
Citigroup shares fall below $2 as U.S. banks plummet
Global stocks slump on bank fears; gold jumps | Video
More Business & Investing News… * Lead drug Cyzact missed Phase III goal

  • Was seen as the main near term investment case

  • Shares down 58 percent

(Adds details)

LONDON, Feb 20 (Reuters) - Skin regeneration specialist Intercytex (ICX.L) announced Friday that its lead drug Cyzact had missed the key target of large-scale trials, sending its shares down 40 percent.

“That was the near-term investment case … effectively it’s now (a case of them) doing something strategic like a merger or being taken over,” said analyst Jacob Plieth at Edison.

The company announced in January that it had enough cash to last it until the end of 2009 after laying off about half of its staff in the UK and the U.S. following the completion of the trial.

By 1557 GMT shares were down 58 percent to 18 pence per share. (Reporting by Ben Deighton; Editing by Matt Scuffham)


#3

It’s sad! just sad!


#4

they are not dead yet. maybe they can try to sell icx-trc or some other technology to another company. but i agree, that it doesnt look good. :frowning:

they said in the article that icx could be taken over. that would be great, since then another company maybe would go on developing icx-trc.


#5

» they are not dead yet. maybe they can try to sell icx-trc or some other
» technology to another company. but i agree, that it doesnt look good. :frowning:
»
» they said in the article that icx could be taken over. that would be
» great, since then another company maybe would go on developing icx-trc.

My thoughts exactly, maybe instead of partenring with bosley for phase III they should sell it to them all together (aderans) and combine their research.
Something tells me Washenik would go for it, they have both just started investigating proto hairs iirc?.


#6

» My thoughts exactly, maybe instead of partenring with bosley for phase III
» they should sell it to them all together (aderans) and combine their
» research.
» Something tells me Washenik would go for it, they have both just started
» investigating proto hairs iirc?.

That would be a risky proposition, Aderans might shelve TRC altogether and stick with their own treatment. The best thing for Intercytex to do at this point is to launch TRC in any country with less restrictions - there are plenty of those! This will not only establish cash flow but also provide valuable data that they can use for phase-III and/or to fine-tune the procedure.


#7

» » My thoughts exactly, maybe instead of partenring with bosley for phase
» III
» » they should sell it to them all together (aderans) and combine their
» » research.
» » Something tells me Washenik would go for it, they have both just
» started
» » investigating proto hairs iirc?.
»
» That would be a risky proposition, Aderans might shelve TRC altogether and
» stick with their own treatment. The best thing for Intercytex to do at this
» point is to launch TRC in any country with less restrictions - there are
» plenty of those! This will not only establish cash flow but also provide
» valuable data that they can use for phase-III and/or to fine-tune the
» procedure.

Keep them coming!! I mean, the jokes…


#8

» » That would be a risky proposition, Aderans might shelve TRC altogether
» and
» » stick with their own treatment. The best thing for Intercytex to do at
» this
» » point is to launch TRC in any country with less restrictions - there
» are
» » plenty of those! This will not only establish cash flow but also
» provide
» » valuable data that they can use for phase-III and/or to fine-tune the
» » procedure.
»
» Keep them coming!! I mean, the jokes…

what’s funny about that?


#9

quote Goata:
The best thing for Intercytex to do at this point is to launch TRC in any country with less restrictions - there are plenty of those! This will not only establish cash flow but also provide valuable data that they can use for phase-III and/or to fine-tune the procedure.

LMAO


#10

» quote Goata:
» The best thing for Intercytex to do at this point is to launch TRC in
» any country with less restrictions - there are plenty of those! This will
» not only establish cash flow but also provide valuable data that they can
» use for phase-III and/or to fine-tune the procedure.

»
» LMAO

Only an idiot with brain the size of a pea would think that’s funny.